Ann: Quarterly report and cash flow statement for Q1 2021, page-42

Hello friends,
by virtue of the enormous content that has been expressed in recent years, added to my insistent research on this title, I no longer have anything particular to add, rather to draw conclusions and ergo:for my professional competence, I consider Pilcher a good accountant, but absolutely a mediocre strategist who has been entrusted with the direction and management of the company, when everything was already decided about how things should go. in essence, I am absolutely convinced that the exit / blackout first of Walker, then of Treagus, took place because the project implemented years earlier has already been formalized, with Pilcher only having to ferry the company to completion in time debt.in the field there are Acadia, which has a fundamental commitment in this project and Neuren which advances with 2591, but with a financial limit that will allow only and exclusively the possible regularization of an experimental process to take place. in all this Pilcher creates various expectations on the market, which by now have no effect because they are those raised in recent years, which have never seriously materialized.in this context I have been waiting for only one event, namely that of a change of ownership that can be with Acadia for 4 $ Au (the latest estimate of just under the analysts is not by chance), or a very strong partnership with a contract that provides for significant divestments of shares by some major biotech and my investigations lead to Roche.as I see it, everything is now reduced to the definition of the company's price; the modalities have already been defined. I only hope that the Pilcher has been invested by his former teammates, also of the possible option of trying to intercept a better proposal than the one defined by Treagus in August three years ago.
Good luck to all.